I-Orlistat

Imininingwane ye-Orlistat powder Base

Igama	I-Orlistat powder
Ukubukeka	I-powder elimhlophe elimhlophe
CAS	96829-58-2
yokuncwaninga izinsimbi kanye namakhemikhali	≥99%
solubility	I-nsoluble emanzini noma utshwala, i-soluble ku-Acetic acid, i-ethyl ester.
isisindo Yamamolekhula	495.7 g / mol
Melt Point	50 ° C
Formula Yamamolekhula	C9H7ClN2O5
Isikali	30mg
Isitoreji Temp	2-8 ° C Kufriza
Grade	I-Pharmaceutical Grade

 

Yini i-orlistat?

I-Orlistat ngumuthi kadokotela okhonjiswe ekwelapheni ukukhuluphala ngokuhambisana nekhalori elincishisiwe eligadiwe kanye nokudla okunamafutha aphansi. Ithengiswa njengomuthi kadokotela ngaphansi kwe-orlistat brand brand Xenical futhi futhi njengomuthi wokulwa nokukhuluphala ngokweqile ngaphansi kwegama lokuhweba i-Alli.

I-Orlistat iyi-inhibitor ehlala isikhathi eside yomlomo yamathumbu emathunjini esebenza ngokuyinhloko ukuvimbela ukumuncwa kwamafutha. I-Orlistat iyindlela egcwele ye-lipstatin, eyi-pancreatic lipase inhibitor yemvelo esebenzayo. I-Orlistat ilula futhi izinzile yingakho ikhethwe ngaphezu kwefomu lomzali i-lipstatin.

I-Orlistat isebenza ukunikela ngokuncipha kwesisindo ngokuhamba kwesikhathi futhi inciphisa amafutha e-visceral. Kodwa-ke kusetshenziswa namanye amasu okunciphisa isisindo njengokudla okunamafutha aphansi nokuzivocavoca umzimba. Izinzuzo zayo njenganoma yiluphi olunye uhlelo lokwehlisa isisindo akuyona into esheshayo kepha uhlelo lwesikhathi eside, olunconywa ngabasebenza kwezokwelapha.

Njengoba isebenza ngokuvimbela ukumuncwa kwamafutha adlayo okunikeza ukuthi kukhishwe kungashintshiwe endleni yabantu, kunezehlakalo eziphezulu zezenzakalo zamathumbu ezenzeka ngokusetshenziswa kwayo. Le miphumela emibi ingahle ibe yimiphumela emibi futhi emibi kakhulu ngomthamo owengeziwe. Ukunqoba noma ukunciphisa imiphumela emibi i-orlistat kufanele ithathwe ngokudla okunamafutha amancane kanye nezithako ze-multivitamin. 

 

Isebenza kanjani i-Orlistat & Kwenzani Empeleni?

I-Orlistat yaziwa njenge-inhibitor ekhethiwe ye-pancreatic ne-gastric lipases. La ma-enzyme (esiswini kanye ne-pancreatic lipases) anomsebenzi wokuwohloka kwe-triglycerides (amafutha / lipid emzimbeni) emathunjini.

I-Orlistat ikakhulu ikhombisa imiphumela yayo ekukhanyeni kwesisu nasemathunjini amancane. I-Orlistat yaziwa ngokubophezela endaweni esebenzayo ye-serine residue ye-gastases ne-pancreatic lipases ukwakha isibopho se-covalent. Ngakho-ke la ma-enzyme ayasebenza futhi awatholakali ku-hydrolyze fat yokudla ngendlela ye-triglycerides ibe ngama-fatty acids nama-monogylcerides angangenwa kalula ngumzimba.

Lapho umsebenzi wabo uvinjelwe, ama-triglycerides atholakala ekudleni komuntu awaguqulwa abe ngama-acid anamafutha angamunca umzimba. Ngakho-ke, ama-triglycerides akhishwa engashintshiwe endleni yomuntu. Njengoba i-triglycerides engashintshiwe ingangeni emzimbeni, lokhu kuphumela ekushodweni kwekhalori okudlala indima ekulawuleni isisindo.

Muva nje, i-orlistat nayo itholwe njenge-inhibitor yesizinda se-thioesterase se-fatty acid synthase (FAS). I-enzyme, i-thioesterase, ixhunyaniswe nokwanda kwamangqamuzana anomdlavuza kepha hhayi ekukhuleni kwamaseli ajwayelekile.

 

Ngabe i-orlistat isebenza uma ungawadli amafutha?

Yebo, i-orlistat isebenza ukunciphisa inani lamafutha afakwe ohlelweni lomzimba. Ngakho-ke asikho isidingo sokuthatha i-orlistat lapho uthatha ukudla ngaphandle kwamafutha. Uma kwenzeka ukwimithi ye-orlistat futhi udla ngaphandle kwamafutha, welulekwa ukuba weqe umthamo ukuze ugweme imiphumela emibi ehambisana nawo.

Kodwa-ke, uma udla ukudla okunamafutha amaningi, ungahle uzwe imiphumela emibi ye-orlistat njengesihlalo esinamafutha, igesi yamathumbu kanye nokubona okunamafutha.

 

I-Orlistat efakazelwe ukunciphisa amafutha we-visceral?

Yebo, impela i-orlistat ikhonjisiwe emtholampilo ukunciphisa amafutha we-visceral. I-Alli (orlistat 60 mg) yamukelwa yi-Food and Drug Administration (i-FDA) njengesidakamizwa esithengelwe ukwelapha ukukhuluphala.

Ucwaningo lwezemitholampilo lukufakazisile lokho i-orlistat akugcini nje ngokunikela ekwehliseni isisindo kodwa futhi kunciphisa kakhulu amafutha e-visceral. Kutholakale ukuthi kunciphise ububanzi bokhalo.

Amafutha e-visceral abizwa nangokuthi amafutha asebenzayo uhlobo oluyingozi lwamafutha agcinwe ngaphakathi kwesisu ngakho-ke luzungeze izitho zangaphakathi ezibaluleke kakhulu njengesibindi, amathumbu namanyikwe. Amanani aphezulu amafutha we-visceral axhumene nezinkinga eziningi zezempilo ezinjengohlobo 2 sikashukela, ukuphazamiseka kwenhliziyo, umdlavuza othile, umfutho wegazi ophakeme kanye nesifo i-Alzheimer's.

Ngesikhathi sokulahleka kwesisindo, amafutha we-visceral aphakathi kwamafutha okuqala alahlekile. Lokhu kuyithuthukisa kakhulu impilo yakho ngokunciphisa izingcuphe zezinkinga eziningi zempilo ezinjengesifo sikashukela, umfutho wegazi ophezulu, nokuphazamiseka kwenhliziyo.

Ocwaningweni olwalubandakanya ababambiqhaza abangama-26, i-orlistat 60 mg (Alli) yayinikezwa kathathu ngosuku ihlangene nekhalori elincishisiwe, ukudla okunamafutha aphansi izinyanga ezintathu. Imiphumela ikhombise ukuthi, i-orlistat ikwazile ukunciphisa kakhulu umjikelezo okhalweni oyisilinganiso samafutha we-visceral. Babike ukwehliswa kwesisindo somzimba ngo-3% no-5.6% wamafutha e-visceral.

Kwesinye isifundo, abantu abangu-123 abanesisindo sokukhuluphala banikezwa i-orlistat kathathu nsuku zonke amasonto angama-24. Babuye belulekwa ukuthi bagcine ukudla okunamafutha amancane. Ngemuva kwenyanga yesithupha, ababambiqhaza babika ukwehliswa kwesisindo somzimba okungu-5.96% nokwehla okushoyo kwamafutha e-visceral ka-15.66%.

 

Ingabe i-orlistat ibangela ukulimala kwesibindi?

I-Orlistat ayikhonjwanga njengembangela eqondile yokulimala kwesibindi kuzo zombili izivivinyo zangaphambi komtholampilo kanye nemitholampilo. Kodwa-ke, ezinye izimo ezingavamile zokulimala kanzima kwesibindi se-orlistat ziye zabikwa ngabantu abasebenzisa i-orlistat.

I-Orlistat ingakhawulela ukusebenza kwe-enzyme ebalulekile ebizwa nge-carboxylesterase-2. I-enzyme, i-carboxyleserase-2 ibamba iqhaza elibalulekile ekuqedeni ubuthi besibindi, izinso nawo wonke umgudu wamathumbu. Lapho le enzyme ivinjelwe kungahle kube nomphumela kubuthi obukhulu bezitho ezibalulekile. 

Ukuphathwa Kwezokudla Nezidakamizwa ngakho-ke kubhalwe ukulimala kanzima kwesibindi njengokukhathazeka ngokuphepha maqondana ne-orlistat. Lokhu kusekelwe emacaleni angaba ngu-13 wokulimala kwesibindi ngemuva kwemakethe ngemuva kokusetshenziswa kwe-orlistat.

Ezifundweni ezenziwe, i-orlistat ayitholakalanga ukuthi iyimbangela eqondile yokulimala okukhulu kwesibindi. Kodwa-ke, ingozi engaba khona yokulimala kwesibindi se-orlistat ehlotshaniswa nayo akumele inganakwa. Kuhle ngaso sonke isikhathi ukuxhumana nodokotela wakho ukuthola izeluleko ezinhle ngaphambi kokuthatha i-orlistat noma esinye isidakamizwa.

 

Izinzuzo ze-Orlistat

Inzuzo enkulu ye-orlistat ukunciphisa isisindo. Eqinisweni, ukulahleka kwesisindo se-orlistat yiyona nzuzo eyinhloko futhi eyaziwayo ekhiqizwa futhi emakethwa ngayo. Isetshenziselwa ukwelapha ukukhuluphala nokusiza ekwehliseni isisindo.

Izinzuzo ze-orlistat yilezi:

 

Ukwelapha ukukhuluphala

Ukukhuluphala ngokweqile nokukhuluphala ngokweqile kubhekise kumafutha angajwayelekile noma ngokweqile anqwabelana emzimbeni. Lokhu kunqwabelana ngokweqile kunengozi enkulu yezempilo. Isilinganiso sokukhuluphala ngokweqile yinkomba yesisindo somzimba evame ukubalwa njengesisindo sakho kumakhilogremu ehlukaniswe yisikwele ukuphakama kwakho ngamamitha.

Ukukhuluphala kuhambisana nezinkinga zempilo njengokuphazamiseka kwenhliziyo, isifo sikashukela, umdlavuza othile nomfutho wegazi ophezulu. Ngenhlanhla, noma ukulahleka kwesisindo okuncane kungavimbela izingqinamba zezempilo ezihambisana nokukhuluphala.

Ngokwemvelo, abantu abaningi abakhuluphele nabakhuluphele ngokweqile banciphisa isisindo ngokubheka ukudla, indlela yokuphila ehambisana nokuzivocavoca umzimba. Izidakamizwa noma imithi yokwehlisa isisindo inqunyelwe ukuhambisana nendlela yokuphila enempilo njengenketho eyengeziwe.

Ukwehla kwesisindo, noma kunjalo, akukwazi ukufinyelelwa ngobusuku obubodwa kepha imvamisa uhlelo lwesikhathi eside. Uhlelo lokwehlisa isisindo luvame ukuba nokudla okufanele, ukuzivocavoca umzimba, nalapho kunesidingo semithi. Uhlelo lokulahlekelwa isisindo luvame ukubhekwa njengoluyimpumelelo lapho ulahlekelwa ngamaphesenti ama-5 noma ngaphezulu kwesisindo sakho sangaphambi kokwelashwa kungakapheli unyaka owodwa. Lokhu kusho ukuthi udinga ukulahlekelwa cishe uhhafu wekhilogremu phakathi neviki lokuqala lokwelashwa. Lokhu kwehla kwesizotha kuqinisekisa ukuthi ugcina isisindo noma ulahlekelwe isisindo esengeziwe ngohlelo oluqhubekayo lokwehlisa isisindo.

I-Orlistat esetshenziswe ngekhalori encishisiwe kanye nokudla okunamafutha amancane kanye nokuzivocavoca umzimba kunika uhlelo olunamandla lokunciphisa isisindo. I-Orlistat, i-lipase inhibitor yamathumbu, inganciphisa inani lamafutha odlayo owaphuzayo ngama-25%. I-Orlistat isebenza ngokuvimbela i-gastases ne-pancreatic lipases. Lawa ama-enzyme ahlukanisa amafutha ekudleni (i-triglycerides) abe yifomu elingabanjwa, ama-fatty acid noma ama-monocerides.

Lapho ukusebenza kwala ma-enzyme kuvinjelwe, umzimba awukwazi ukumunca ama-calories kepha kunalokho amafutha akhishwa angadliwe endle. Lesi yisici esibalulekile ekulawuleni isisindo.

Ucwaningo olwenziwe ngemitholampilo luye lwenziwa futhi lwafakazela ukuthi izinzuzo zokuncipha kwesisindo se-orlistat zinamandla ngempela.

Ocwaningweni olubandakanya ababambiqhaza abangama-3,305 ababekhuluphele ngokweqile, i-orlistat yayinikezwa ama-120 mg kathathu nsuku zonke iminyaka engu-4. Abahlanganyeli baphinde belulekwa ukuthi banamathele ekudleni okuncane kwekhalori okungekho ngaphezu kwama-30% wama-calories. Balulekiswa ukuthi bazivocavoce ngokuhambahamba usuku ngalunye.

Lolu cwaningo luthole ukuthi, isisindo esilahlekile ngonyaka wokuqala sasicishe sibe ngu-10.6 kg. Noma ababambiqhaza bekhuluphele eminyakeni emithathu edlule yecala, ekugcineni, isisindo esilinganisiwe esilahlekile besingaba ngu-5.8 kg.

Kwesinye isifundo se-orlistat sonyaka owodwa esenziwe satholwa siphumela ku-5% noma ngaphezulu kwesisindo.

Ezinye izinzuzo ze-orlistat zifaka;

 

I-Orlistat Nciphisa ubungozi besifo sikashukela sohlobo 2

Uhlobo lwe-2 sikashukela noma isifo sikashukela yisimo esibi esinomthelela ekusetshenzisweni kweshukela (glucose) emzimbeni. Kwenzeka lapho imizimba yethu ingazweli ku-insulin. I-insulin yi-hormone ebhekele ukulawula ukugeleza koshukela (glucose) emzimbeni. Kungenzeka futhi uma amanyikwe engakhiqizi inani elanele le-insulin ukugcina amazinga e-glucose afanele emzimbeni.

Yize izimbangela eziqondile zokungazweli kwe-insulin zingaziwa kahle, ukukhuluphala ngokweqile kungenye yezinto ezinomthelela ekuthuthukiseni uhlobo lwesifo sikashukela sohlobo lwe-2. Thayipha izimpawu zesifo sikashukela sesi-2 kungaba lula ukuziba njengoba zikhula kancane, kepha-ke, uma kungelashwa kungaholela ezinkingeni eziningi. Uhlobo oluthuthukile lwesifo sikashukela esingu-2 lungaholela ezinkingeni eziningi ezifana nomfutho wegazi ophezulu, izifo zenhliziyo nemithambo yegazi nokuhlaselwa yisifo senhliziyo. Lezi zimpawu nezimpawu zibandakanya ukuchama njalo, ukoma okwandayo, ukuncipha komzimba ungahlosile, ukukhathala, ukungaboni kahle, ukutheleleka okuvamile, amanxeba apholisa kancane nokuba mnyama kwezinye izindawo zesikhumba ezifana nentamo namakhwapha.

I-Orlistat isidakamizwa esinamandla sokulahlekelwa isisindo yingakho idlala indima ebaluleke kakhulu ekuvimbeleni ukuqala kohlobo lwesifo sikashukela sohlobo lwe-2. Izenzo ezithile zemodi ye-orlistat ekhonjwe ukuthi izodlala indima kuhlobo lwesifo sikashukela se-2 ifaka phakathi ukukhulisa ukuzwela kwe-insulin, ukunciphisa i-postprandial plasma non-esterified fatty acids, ukunciphisa noma ukuvimbela ukugaywa kwamafutha adlayo, ukunciphisa amafutha we-visceral, nokunciphisa uketshezi lwe-peptide-1 efana ne-glucagon emathunjini amancane aphansi.

Esifundweni nabantu abakhuluphele, i-orlistat ephelezelwa indlela yokuphila enempilo (ukudla okunamafutha amancane nokuvivinya umzimba) kutholakale ukuthi yehlisa kakhulu izehlakalo zohlobo lwesifo sikashukela sohlobo 2. Futhi kwaholela ekulahlekelweni okukhulu kwesisindo.

Olunye ucwaningo lwenziwa nabantu abakhuluphele noma abakhuluphele kakhulu abanesifo sikashukela sohlobo 2. I-Orlistat 120 mg yayinikezwa kathathu nsuku zonke izinyanga eziyisithupha noma eziyishumi nambili.

Kutholwe ukuthi ngaphandle kwe- umphumela we-orlistat wesisindo, i-orlistat ikwazile ukuthuthukisa ukulawulwa kwe-glycaemia. Amapharamitha we-glycaemia athuthukisiwe abe ukwehla kokuzila ukudla kwe-plasma glucose (FPG) ne-hemoglobin A1c (HbA1c). Ukulawulwa okuthuthukisiwe kwe-glycaemia bekuzimele ekwehliseni isisindo.

 

I-Orlistat  Inganciphisa umfutho wegazi ophakeme

Umfutho wegazi ophakeme owaziwa nangokuthi umfutho wegazi ophakeme yisimo sempilo esenzeka lapho umfutho wegazi lakho ukhuphukela emazingeni aphezulu kakhulu futhi uvame ukuya emazingeni angenampilo. Umfutho wegazi uyanda lapho imithambo yegazi iba mincane.

Ukuchayeka isikhathi eside kumfutho wegazi ophakeme kungaholela ezimweni ezingalapheki ezithinta izitho ezibalulekile njengenhliziyo, izinso noma yimaphi amehlo. Izimpawu ezivame kakhulu zomfutho wegazi ophezulu ukuphathwa yikhanda, ukuphuma kwegazi, ukushintsha kombono, isiyezi, ubuhlungu besifuba, ukuphefumula okuncane ngisho negazi emchameni.

I-Orlistat eyi-lipases inhibitor iyasiza ekuvimbeleni ukumuncwa kwamafutha adlayo ajwayele ukuvimba imithambo. Ngakho-ke i-Orlistat inganciphisa kancane umfutho wegazi ovame ukwenzeka ngenxa yokukhuluphala ngokweqile.

Ocwaningweni oluthinta abantu abakhuluphele noma abakhuluphele ngokweqile abangama-628 abanesifo somfutho wegazi ophezulu, i-orlistat yanikezwa ku-120 mg kathathu ngosuku unyaka owodwa. Lezi ziguli zazinengcindezi ephezulu engalawulwa ye-diastolic yengcindezi ye-systolic ehlukile. Ngaphezu kwemithi kadokotela ye-orlistat, iziguli esizeluleke ukuthi zigcine ukudla okunamafutha aphansi kuleso sikhathi.

Ucwaningo lubike ukwehla okukhulu kwesisindo kanye nokwehla kokubili kwe-diastolic kanye ne-systolic hypertension. Baqopha ukwehliswa kwe--9.4 mmHg ku-systolic hypertension kanye no -7.7 mmHg ukunciphisa ingcindezi ye-diastolic.

Lokhu kukhombisa ukuthi i-orlistat ingasetshenziswa ekuphathweni komfutho wegazi ophezulu kubantu abakhuluphele noma abakhuluphele ngokweqile.

Lokhu kuncishiswa okuncane komfutho wegazi ophakeme kuxhumene nokusetshenziswa kwesikhathi eside kwe-orlistat okuhambisana nokudla okuncane kwekhalori nokuzivocavoca umzimba.

Kwesinye isifundo, ukusetshenziswa kwe-log-term ye-orlistat kwatholakala ukuthi kunciphisa kancane umfutho wegazi ngokunciphisa okushoyo okungu-2.5 mmHg kwengcindezi ye-systolic kanye no-1.9 mmHg we-diastolic blood pressure. 

 

I-Orlistat  Yehlisa inani kanye ne-LDL cholesterol

I-low-density lipoprotein cholesterol (i-LDL cholesterol) imvamisa ibizwa nge-cholesterol embi ngoba iqoqana ezindongeni zemithambo yegazi ngaleyo ndlela kwandise ubungozi bezinkinga zempilo njengokuphazamiseka kwenhliziyo nokushaywa unhlangothi.

Ingqikithi ye-cholesterol iqukethe i-low-density lipoprotein (LDL) ne-high-density lipoprotein (HDL) cholesterol. Ukuphakama kwezinga le-cholesterol ephelele kuphakamisa ubungozi bokuphazamiseka kwenhliziyo.

I-Orlistat kubikwe ukuthi yehlisa i-cholesterol ye-LDL ngaphezu kwezinzuzo zayo zokwehlisa isisindo.

Ocwaningweni olubandakanya iziguli ezikhuluphele noma ezikhuluphele ngokweqile, i-orlistat yanikezwa ngomthamo ka-120 mg kathathu nsuku zonke amasonto angama-24. Iziguli bezine-BMI (inkomba yomzimba) engu-27-40 kg / m2 ne-hypercholesterolemia (low-density-lipoprotein cholesterol, LDL-C, 4.1-6.7 mol / l).

I-Orlistat itholwe ukuthi yehlisa kakhulu isisindo kanye nengqikithi kanye ne-LDL cholesterol. Kuphinde kwaboniswa ukuthi umphumela wokwehlisa i-cholesterol ye-LDL ubuzimele ngezinzuzo zokwehlisa isisindo. Kulolu cwaningo i-orlistat ibekezeleleke kahle ngaphandle kwesigameko esiphakeme semicimbi yamathumbu.

Kwesinye isifundo, abantu abangama-448 abanamazinga aphezulu kakhulu e-cholesterol banikezwa i-orlistat ku-120 mg kathathu ngosuku cishe izinyanga eziyisithupha. Iziguli ziphinde zayalwa ukuba zinamathele kukhalori elincishisiwe kanye nokudla okunamafutha amancane. Lokhu kuholele ekulahlekelweni kwesisindo okubalulekile ngokuncipha kwesisindo okuphakathi kuka-6 kg. Ngokufanayo, kube nokuncipha okukhulu kwe-cholesterol ephelele ne-low-density lipoprotein cholesterol ngo-7.4-25 mg / dL.

Baqhubeka bathi umphumela wokwehlisa i-cholesterol ye-orlistat ubuzimele ku-orlistat isisindo ukulahleka imiphumela.

 

Ukusebenzisana kwe-Orlistat

Ukusebenzisana kwezidakamizwa kusho ukuthi izidakamizwa ezahlukahlukene zihlobana noma zithonye kanjani abanye. Lokhu kuhlangana kwezidakamizwa kunomthelela ekusebenzeni kwezinye izidakamizwa futhi kungakhuphula izehlakalo zemiphumela emibi ehambisana nokusetshenziswa komuthi othile. Ukusebenzisana kwe-Orlistat nezinye izidakamizwa kutholakele.

Ngaphandle kokuhlangana nezinye izidakamizwa, i-orlistat ayinconyiwe ukuthi isetshenziswe ngabesifazane abakhulelwe noma abancelisayo. Akufanele futhi kusetshenziswe yizingane ezingaphansi kweminyaka eyi-12.

Kuyalulekwa kakhulu ukuthi ugcine uhlu lwezidakamizwa noma imishanguzo futhi uhlale udalula umhlinzeki wakho wezokunakekelwa kwezempilo ukuze uthole izeluleko ezinhle kakhulu ngokusebenzisana okungenzeka kube khona. Lokhu kuhlangana kwezidakamizwa kwe-orlistat kungaba yingozi kakhulu empilweni yakho kudlula izinzuzo ezithathiwe. Ngakho-ke, ungakunaki lokhu kuhlangana kepha kunalokho thatha izinyathelo zokuqapha.

Okunye ukuxhumana okwaziwayo kwe-orlistat;

 

Ukusebenzisana kwe-Orlistat nabanciphisi begazi

Ama-thinner egazi yimithi esetshenziswa ekwelapheni ukuphazamiseka kwenhliziyo ethile nezimo ezikubeka engcupheni yamahlule egazi ayingozi. Imvamisa zisiza igazi ukuba ligeleze kahle emithanjeni yegazi. Iphinde ivimbele amahlule ukuba akhe noma abe makhulu.

Lezi zinciphisi zegazi zifaka phakathi i-warfarin, i-heparin, i-apixaban, i-dabigatran ne-rivaroxaban powder phakathi kwabanye.

I-Orlistat inganciphisa ukumuncwa kukavithamini K. IVitamin K yiqembu lamakhompiyutha okungukuthi iVitamin k1 kanye ne-vitamin K2. UVitamin K ubamba iqhaza elibalulekile ekusizeni igazi ukuba lijiye futhi nokuvikela ukopha ngokweqile. Lapho ukumuncwa kwayo kunqunyelwe, uzojwayela ukuphuma igazi kalula futhi kalula. Yingakho ukuthatha izinciphisi zegazi kanye ne-orlistat kwandisa amathuba akho wokopha ngokweqile futhi kungakwenza uphume igazi kalula.

Okunye ukunakekelwa kwezempilo kuzokweluleka ukuthi ulungise isilinganiso sakho sabanciphisi begazi ukuze ukwazi ukubasebenzisa kanye ne-orlistat. Kodwa-ke, ngaphandle kokuthi kunconyiwe ungalokothi uguqule imithamo yezidakamizwa.

 

Ukusebenzisana kwe-Orlistat nemithi ye-HIV

Lezi zibizwa nangokuthi imishanguzo yokuthithibalisa leli gciwane. Imishanguzo yokuthithibalisa igciwane lengculazi inikezwa abantu abaphethwe yigciwane lesandulela-ngculazi (i-HIV) ukuze kunciphise inani legciwane egazini ngakho-ke kwenyusa izinga lokusinda ezigulini.

Izidakamizwa zihlanganisa i-lopinavir, i-ritonavir, i-atazanavir, i-efavirenz, i-tenofovir ne-emticitabine.

Lapho le mithi ithathwa kanye ne-orlistat, kuye kwabikwa ukuthi i-antiretroviral virology iyancipha ngakho-ke inani legciwane le-HIV lenyuka esikhundleni salokho. Kufanele-ke ugweme ukusebenzisa i-orlistat kanye nezidambisigciwane ngokuhambisana.

Uma kwenzeka kunesidingo sokuzihlanganisa, inani legciwane lesandulela ngculaza kufanele libhekwe ngeso elibukhali futhi ukusetshenziswa kwe-orlistat kufanele kuyekwe uma umthamo wegciwane kutholakala ukuthi uyanda.

 

Ukusebenzisana kwe-Orlistat nemithi yokubanjwa

Izidakamizwa zokubamba ezibizwa nangokuthi imishanguzo yokulwa nesifo sokuwa zisetshenziselwa ukunciphisa izimpawu zokuquleka / zesifo sokuwa. Amafutha ayinto ebalulekile ezigulini ezinesithuthwane. Ngakho-ke lokhu kuholela ekutholeni isisindo njengomphumela omubi wale mithi. Izidakamizwa zokubanjwa zihlanganisa i-lamotrigine.

Ngakolunye uhlangothi i-Orlistat inciphisa ukumuncwa kwamafutha. Uma isetshenziswa kanye nemithi elwa nesifo sokuwa, i-orlistat kubikwe ukuthi inciphisa ukumuncwa kwemithi.

Eminye imibiko ye-anecdotal ibika ukuthi i-orlistat ithathiwe kanye nezidakamizwa zokubanjwa kwandisa ukwenzeka kokuquleka.

 

Ukusebenzisana kwe-Orlistat ne-cyclosporine

I-Cyclosporine ebizwa nangokuthi i-ciclosporin imithi yokwelashwa ye-immunosuppressant. Isetshenziselwa ukuvimbela umzimba ekwenqabeni izitho ngemuva kokufakelwa kabusha.

Uma isetshenziswa ndawonye, ​​i-orlistat inciphisa kakhulu amazinga e-plasma we-cyclosporine. Lokhu kungenxa yokuthi i-orlistat ingaphazamisa ukumuncwa kwale mithi.

Abanye ochwepheshe bezokwelapha bancoma ukungasebenzisi i-orlistat ngenkathi usebenzisa i-cyclosporine. Kodwa-ke, abanye odokotela batusa ukuthatha i-cyclosporine cishe ngamahora ama-3 ngemuva kokuthatha i-orlistat.

 

Ukusebenzisana kwe-Orlistat ne-amiodarone

Lokhu kubhekisela kumuthi olwa nokuhleleka osetshenziselwa ukubuyisela ukushaya kwenhliziyo okujwayelekile kanye nokugcina isigqi esiqinile futhi esijwayelekile.

I-Orlistat ikhonjisiwe ukuthi iphazamisa ukumuncwa kwe-amiodarone egazini. lokhu kuvinjelwa kuholela ekushayeni kwenhliziyo okungavamile okuyingozi enkulu empilweni.

 

Ukusebenzisana kwe-Orlistat nge-levothyroxine

I-Levothyroxine yisidakamizwa esisetshenziswa ekwelapheni umsebenzi ophansi we-thyroid futhi welapha izinhlobo ezithile zama-goiters. Umsebenzi we-thyroid ophansi ubizwa ngokuthi yi-hypothyroidism futhi ubandakanya izimpawu ezifana nokukhathala, isikhumba esomile, inkumbulo engasebenzi kahle, ukuzuza kwesisindo, ukushesha, ubuthakathaka bemisipha, izinga eliphakeme le-cholesterol egazini, elinzima kunezikhathi ezejwayelekile noma ezingajwayelekile zokuya esikhathini, izinga lokushaya kwenhliziyo ephansi, ukucindezeleka kanye ne-goiters .

Ukuphathwa ngokubambisana kwe-levothyroxine ne-orlistat kubikwe ukuthi kwehlise izinga le-levothyroxine elifakwe. I-Orlistat kubikwa ukuthi ibopha i-levothyroxine yingakho, ivimba ukumuncwa kwayo emathunjini. Lokhu kungaholela ku-hypothyroidism enamandla engaholela ezinkingeni zezempilo njengokungazali, ukukhuluphala ngokweqile, ubuhlungu, nokuphazamiseka kwenhliziyo. 

 

Ukusebenzisana kwe-Orlistat ngamavithamini ancibilika emafutheni

I-Orlistat ingavimbela ukumuncwa kwamavithamini ancibilika ngamafutha kanye nezakhamzimba ezithile. Amavithamini ancibilikayo anamafutha ahlanganisa amavithamini A, D, E, K ne-beta-carotene.

Kunconywa kakhulu ukuthatha isithasiselo se-multivitamin esiqukethe amavithamini ancibilikayo. Isengezo se-multivitamin kufanele sithathwe okungenani amahora we-2 ngaphambi noma ngemuva kokuthatha i-orlistat.

 

Imiphumela emibi ye-Orlistat

Imiphumela emibi kakhulu ye-orlistat yenzeka ngenxa yamafutha angadliwe adlula ohlelweni lwakho lokugaya ukudla. Ngokuyinhloko imiphumela yasesiswini njengoba umzila oyinhloko we-orlistat ungowomlomo futhi amafutha angashintshiwe akhishwa endleni.

Imiphumela emibi ye-orlistat yenzeka emasontweni ambalwa okuqala wokuyithatha futhi ingahamba. Kodwa-ke, ezinye izimpawu zingaqhubeka. Imiphumela emibi ingavela kaningi uma umthamo ungalungile.

Le miphumela engemihle ingafinyelelwa ngokuthatha umuthi ofanele ngenkathi ulandela izeluleko zikadokotela wakho ekugcineni ikhalori elincishisiwe, ukudla okunamafutha aphansi kanye nokuzivocavoca umzimba.

Umthamo we-orlistat onconyiwe ngu-120 mg uthathwa kathathu nsuku zonke. I-Orlistat kufanele ithathwe ngaphambi kokudla njengoba ivame ukuvimbela cishe ama-30% wamafutha adlayo ukuthi angangeni. Imithamo ephakeme noma i-orlistat ayibangeli imiphumela enamandla kepha ingaholela kweminye imiphumela emibi.

Le miphumela emibi ye-orlistat ifaka;

• Ukuphuthuma noma ubunzima bokulawula ukuhamba kwamathumbu
• Ukuhamba kwamathumbu okuxekethile nokuvamile
• Izihlalo ezinamafutha noma ezinamafutha
• Ubuhlungu besisu noma be-rectum noma ukungaphatheki kahle kwesisu
• Ukudlulisa igesi kaningi ngokukhishwa kwe-anal oily.

Imiphumela emibi ye-orlistat engenhla ingase ibe yimbi kakhulu uma uthatha amafutha amaningi kunalokho obekufanele ukwenze uma usebenzisa imithi ye-orlistat.

Eminye imiphumela emibi ye-orlistat yize ingavamile ingavela. Uyelulekwa ukuthi ufune usizo lwezokwelapha ngokushesha lapho ubona le miphumela. Le miphumela emibi ye-orlistat ingenzeka kumthamo ongaphezulu komuthi. Imiphumela emibi ifaka phakathi;

• Ukuphathwa yikhanda
• ukukhathazeka
• Ukuphazamiseka kumjikelezo wokuya esikhathini
• Ukuthola kunzima ukuphefumula
• Kunzima ukugwinya
• Ubuhlungu obukhulu besisu obungeke buphele
• Isiyezi esikhulu
• Ukuvuvukala (ikakhulukazi olimini, emphinjeni noma ebusweni).

Njengoba ezinye izimo ezingavamile kakhulu zokulimala kanzima kwesibindi ziye zaxhunyaniswa nokusetshenziswa kwe-orlistat, qiniseka ukuthi ubheka izimpawu zokulimala kwesibindi. Kufanele ume ngokushesha futhi ufune usizo lwezokwelapha uma uhlangabezana nalezi zimpawu ezilandelayo zokulimala kwesibindi;

• Ukukhathala okungapheliyo
• Ukulahlekelwa kwesifiso
• Isifuba noma ukulunywa okunzima nokuphikelelayo
• Ukungabi namandla
• Ukuhlanza noma isicanucanu
• I-jaundice (ukuphuzi kwamehlo noma isikhumba)
• Izitulo ezinombala okhanyayo / eziphaphathekile
• Umchamo omnyama
• Ukudumaza kalula
• Ukuvuvukala emaqakaleni noma emilenzeni.

Sibhale imiphumela emibi eminingi ye-orlistat futhi ngisho nokubi okuhambisana nayo, noma kunjalo, hlala uzimisele ukubona noma yimiphi imiphumela ongase ube nayo futhi ukhulume nomhlinzeki wakho wezokunakekelwa kwempilo. Qiniseka ukuthi ulandela imiyalo ngokucophelela kumthamo nokusetshenziswa okufanele kwe-orlistat ukuze ususe iningi lale miphumela. 

Njengezidakamizwa eziningi, imiphumela emibi ingavela ekuqaleni kokwelashwa futhi iphele ngokusetshenziswa okuqhubekayo kepha, eminye imiphumela emibi ingaqhubeka. Ukweqisa ngokweqile ngomunye umnikeli ovamile ezimweni zemiphumela emibi eminingi, ngakho-ke awuthathi okuningi kwe-orlistat kunokunconywa.

 

Kuzo yiwaphi Thenga i-Orlistat?

Imikhiqizo equkethe i-orlistat ivela ngamagama emikhiqizo e-orlistat ehlukile. Lokhu kungenxa yokuthi abakhiqizi be-orlistat bayehluka kanye nokuhlushwa.

Umthamo ophansi we-orlistat wenzeka kumagama we-orlistat brand njengo-Alli no-Orlos. Lokhu kungathengwa kalula ku-inthanethi kubakhiqizi abaningi be-orlistat nabahlinzeki be-orlistat. Kodwa-ke, uma ubheka i-orlistat ithenge kosokhemisi abagunyaziwe. I-CMOAPI ingomunye wabakhiqizi be-orlistat futhi banikela ngemikhiqizo esezingeni eliphakeme. I- I-CMOAPI inkampani ibe sebhizinisini isikhathi eside yingakho iqinisekisa ikhwalithi kanye ne-orlistat ehlanganiswe kahle.

Qaphela kakhulu izidakamizwa ezingekho emthethweni. Funda amalebuli ngokucophelela ukuze uqonde ukusetshenziswa okufanele kwezidakamizwa. Bheka umakhi we-orlistat noma ngenye indlela abahlinzeki be-orlistat, usuku lokwenziwa kanye nosuku lokuphelelwa yisikhathi. Qiniseka ukuthi ubheka noma yimiphi imiphumela emibi ekhonjisiwe nesixwayiso. Isibonelo, ukulimala kwesibindi se-orlistat kungenye yezexwayiso noma kunalokho okukhonjiswa yi-Food and Drug Administration (i-FDA) yabasebenzisi ukuthi baqaphele lapho bethatha imithi.

 

Okubhekwayo

1. “Ilebuli ye-orlistat yase-US” (PDF). I-FDA. Agasti 2015. Ibuyiswe ngomhlaka 18 Ephreli 2018. Ukubuyekezwa kwelebula bheka ikhasi lenkomba le-FDA le-NDA 020766
2. UBarbier P, uSchneider F (1987). "Ama-syntheses we-tetrahydrolipstatin nokulungiswa okuphelele kwe-tetrahydrolipstatin ne-lipstatin". Helvetica Chimica Acta. 70 (1): 196-202. i-doi: 10.1002 / hlca.19870700124.
3. UBodkin J, uHumphries E, uMcLeod M (2003). “Ukuhlanganiswa okuphelele kwe- (-) - tetrahydrolipstatin”. Ijenali yase-Australia yeKhemistry. 56 (8): 795-803. i-doi: 10.1071 / CH03121.
4. Filippatos, Theodosios & Derdemezis, Christos & Gazi, Irene & Nakou, Eleni & Mikhailidis, Dimitri & Elisaf, Moses. (2008). Imiphumela Emibi Ehambisana Ne-Orlistat nokusebenzisana kwezidakamizwa Ukuphepha kwezidakamizwa: iphephabhuku lamazwe omhlaba lobuchwepheshe bezokwelapha kanye nesipiliyoni sezidakamizwa 31. 53-65. 10.2165 / 00002018-200831010-00005.
5. USharma, AM, noGolay, A. (2002). Umphumela wokwehliswa kwesisindo okubangelwa i-orlistat kumfutho wegazi nokushaya kwenhliziyo ezigulini ezikhuluphele ezine-hypertension. Ijenali yomfutho wegazi ophezulu, 20(9), 1873–1878. doi.org/10.1097/00004872-200209000-00034.
6. Kufakwe isitayela ngosonhlamvukazi omncane ephaketheni, kanye nebha ngaphezulu kwe- i (okungukuthi, “allī”), kepha kufakwa ngofeleba ngokujwayelekile kule ncwajana.
7. UZhi J, uMelia AT, u-Eggers H, uJoly R, uPatel IH (1995). "Ukubuyekezwa kokumuncwa okulinganiselwe kwe-orlistat, i-lipase inhibitor, kumavolontiya abantu aphilile". UJ Clin Pharmacol. 35 (11): 1103-8. i-doi: 10.1002 / j.1552-4604.1995.tb04034.x. I-PMID 8626884.